Targeting Senescence and GATA4 in Age-related Cardiovascular Disease: a Comprehensive Approach

Overview

Journal Biogerontology

Date 2025 Jan 20

PMID 39831933

Authors

Mohd Imran

Abdulmalik S A Altamimi

Muhammad Afzal

M Arockia Babu

Kavita Goyal

Suhas Ballal

Pawan Sharma

Fadiyah Jadid Alanazi

Abeer Nuwayfi Alruwaili

Nouf Afit Aldhafeeri

Haider Ali

Affiliations

Soon will be listed here.

Abstract

The growing prevalence of age-related cardiovascular diseases (CVDs) poses significant health challenges, necessitating the formulation of novel treatment approaches. GATA4, a vital transcription factor identified for modulating cardiovascular biology and cellular senescence, is recognized for its critical involvement in CVD pathogenesis. This review collected relevant studies from PubMed, Google Scholar, and Science Direct using search terms like 'GATA4,' 'cellular senescence,' 'coronary artery diseases,' 'hypertension,' 'heart failure,' 'arrhythmias,' 'congenital heart diseases,' 'cardiomyopathy,' and 'cardiovascular disease.' Additionally, studies investigating the molecular mechanisms underlying GATA4-mediated regulation of GATA4 and senescence in CVDs were analyzed to provide comprehensive insights into this critical aspect of potential treatment targeting. Dysregulation of GATA4 is involved in a variety of CVDs, as demonstrated by both experimental and clinical research, comprising CAD, hypertension, congenital heart diseases, cardiomyopathy, arrhythmias, and cardiac insufficiency. Furthermore, cellular senescence enhances the advancement of age-related CVDs. These observations suggested that therapies targeting GATA4, senescence pathways, or both as necessary may be an effective intervention in CVD progression and prognosis. Addressing age-related CVDs by targeting GATA4 and senescence is a broad mechanism approach. It implies further investigation of the molecular nature of these processes and elaboration of an effective therapeutic strategy. This review highlights the importance of GATA4 and senescence in CVD pathogenesis, emphasizing their potential as therapeutic targets for age-related CVDs.

References

Abbasi S, Mohsen-Pour N, Naderi N, Rahimi S, Maleki M, Kalayinia S . analysis of variants demonstrates main contribution to congenital heart disease. J Cardiovasc Thorac Res. 2022; 13(4):336-354. PMC: 8749364. DOI: 10.34172/jcvtr.2021.45. View

Chari A, Palladino A, Craft N, Sawyers C . Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Mol Cell Biol. 1999; 19(7):5143-54. PMC: 84357. DOI: 10.1128/MCB.19.7.5143. View

Adepu S, Ramakrishna S . Controlled Drug Delivery Systems: Current Status and Future Directions. Molecules. 2021; 26(19). PMC: 8512302. DOI: 10.3390/molecules26195905. View

Afouda B . Towards Understanding the Gene-Specific Roles of GATA Factors in Heart Development: Does GATA4 Lead the Way?. Int J Mol Sci. 2022; 23(9). PMC: 9099915. DOI: 10.3390/ijms23095255. View

Ahmad F . Dietary patterns and the risk of cardiovascular diseases. Nutr Health. 2023; 29(4):609-610. DOI: 10.1177/02601060231216523. View

Anastasiou D, Yu Y, Israelsen W, Jiang J, Boxer M, Hong B . Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat Chem Biol. 2012; 8(10):839-47. PMC: 3711671. DOI: 10.1038/nchembio.1060. View

Angiari S, Runtsch M, Sutton C, Palsson-McDermott E, Kelly B, Rana N . Pharmacological Activation of Pyruvate Kinase M2 Inhibits CD4 T Cell Pathogenicity and Suppresses Autoimmunity. Cell Metab. 2019; 31(2):391-405.e8. PMC: 7001035. DOI: 10.1016/j.cmet.2019.10.015. View

Asp M, Giacomello S, Larsson L, Wu C, Furth D, Qian X . A Spatiotemporal Organ-Wide Gene Expression and Cell Atlas of the Developing Human Heart. Cell. 2019; 179(7):1647-1660.e19. DOI: 10.1016/j.cell.2019.11.025. View

Bailleul J, Ruan Y, Abdulrahman L, Scott A, Yazal T, Sung D . M2 isoform of pyruvate kinase rewires glucose metabolism during radiation therapy to promote an antioxidant response and glioblastoma radioresistance. Neuro Oncol. 2023; 25(11):1989-2000. PMC: 10628945. DOI: 10.1093/neuonc/noad103. View

10.

Baman J, Ahmad F . Heart Failure. JAMA. 2020; 324(10):1015. DOI: 10.1001/jama.2020.13310. View

11.

Banes A, Florian J, Watts S . Mechanisms of 5-hydroxytryptamine(2A) receptor activation of the mitogen-activated protein kinase pathway in vascular smooth muscle. J Pharmacol Exp Ther. 1999; 291(3):1179-87. View

12.

Bao M, Li G, Huang X, Tang L, Dong L, Li J . Long Noncoding RNA LINC00657 Acting as a miR-590-3p Sponge to Facilitate Low Concentration Oxidized Low-Density Lipoprotein-Induced Angiogenesis. Mol Pharmacol. 2018; 93(4):368-375. DOI: 10.1124/mol.117.110650. View

13.

Barreto S, Hamel L, Schiatti T, Yang Y, George V . Cardiac Progenitor Cells from Stem Cells: Learning from Genetics and Biomaterials. Cells. 2019; 8(12). PMC: 6952950. DOI: 10.3390/cells8121536. View

14.

Bazgir F, Nau J, Nakhaei-Rad S, Amin E, Wolf M, Saucerman J . The Microenvironment of the Pathogenesis of Cardiac Hypertrophy. Cells. 2023; 12(13). PMC: 10341218. DOI: 10.3390/cells12131780. View

15.

Beaufils M . [Hypertension in pregnancy]. Arch Mal Coeur Vaiss. 2001; 94(10):1077-86. View

16.

Behiry E, Al-Azzouny M, Sabry D, Behairy O, Salem N . Association of NKX2-5, GATA4, and TBX5 polymorphisms with congenital heart disease in Egyptian children. Mol Genet Genomic Med. 2019; 7(5):e612. PMC: 6503026. DOI: 10.1002/mgg3.612. View

17.

Bhullar S, Dhalla N . Angiotensin II-Induced Signal Transduction Mechanisms for Cardiac Hypertrophy. Cells. 2022; 11(21). PMC: 9657342. DOI: 10.3390/cells11213336. View

18.

Bilbrough T, Piemontese E, Seitz O . Dissecting the role of protein phosphorylation: a chemical biology toolbox. Chem Soc Rev. 2022; 51(13):5691-5730. DOI: 10.1039/d1cs00991e. View

19.

Bing P, Liu W, Zhai Z, Li J, Guo Z, Xiang Y . A novel approach for denoising electrocardiogram signals to detect cardiovascular diseases using an efficient hybrid scheme. Front Cardiovasc Med. 2024; 11:1277123. PMC: 11064874. DOI: 10.3389/fcvm.2024.1277123. View

20.

Bisping E, Ikeda S, Kong S, Tarnavski O, Bodyak N, McMullen J . Gata4 is required for maintenance of postnatal cardiac function and protection from pressure overload-induced heart failure. Proc Natl Acad Sci U S A. 2006; 103(39):14471-6. PMC: 1636702. DOI: 10.1073/pnas.0602543103. View